Clinical characteristics of patients with prolonged disease-free survival after primary treatment in advanced ovarian cancer: A brief report

International Journal of Gynecological Cancer

Volumn 21, Issue 3, 2011, Pages 475-477

  Milam, Michael R ^a   Harrell, Robyn ^b   Bassett, Roland ^b   Parker, Lynn P ^a   Metzinger, Daniel S ^a   Ramirez, Pedro T ^b  

^a UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Neoadjuvant chemotherapy; Ovarian cancer; Survival

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; PACLITAXEL; PLATINUM; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HOSPITALIZATION; HUMAN; OVARY CANCER; PRIORITY JOURNAL; RISK; TREATMENT OUTCOME; ADJUVANT THERAPY; CANCER STAGING; COMPARATIVE STUDY; DRUG EFFECT; METABOLISM; MORTALITY; OVARY; OVARY TUMOR; SURVIVAL RATE; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80051631385     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31820bf251     Document Type: Article

References (6)

1. Vergote I, Amant F, Leunen K. Neoadjuvant chemotherapy in advanced ovarian cancer: what kind of evidence is needed to convince US gynaecological oncologists? Gynecol Oncol. 2010;119:1-2.
2. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-953.
3. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
4. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43. (Pubitemid 43048949)
5. Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114:26-31.
6. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003;21:2460-2465. (Pubitemid 46606325)